ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

IDH Wildtype Glioblastoma
Recurrent Astrocytoma
IDH Wildtype Recurrent Glioblastoma
Resectable Astrocytoma
Resectable Glioblastoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Echocardiography Test
DRUG: EGFR Inhibitor ERAS-801
OTHER: Fludeoxyglucose F-18
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography
PROCEDURE: Surgical Procedure

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

National Institutes of Health (NIH)
United States Department of Defense